Phase II study of topotecan and bevacizumab in advanced, refractory non--small-cell lung cancer.

@article{Powell2013PhaseIS,
  title={Phase II study of topotecan and bevacizumab in advanced, refractory non--small-cell lung cancer.},
  author={Steven Francis Powell and Amer M Beitinjaneh and Mathewos Z. Tessema and Robin L. Bliss and Robert Arthur Kratzke and Joseph Leach and Arkadiusz Z. Dudek},
  journal={Clinical lung cancer},
  year={2013},
  volume={14 5},
  pages={
          495-501
        }
}
BACKGROUND This clinical trial evaluated whether topotecan in combination with bevacizumab improved progression-free survival (PFS) in patients with advanced, refractory non--small-cell lung cancer in a second-line setting. PATIENT AND METHODS Patients aged 18 years old and older received topotecan (4.0 mg/m(2)) on days 1, 8, and 15, and bevacizumab (10 mg/kg) on days 1 and 15 as intravenous infusions on a 28-day treatment cycle. Available tumor specimens were analyzed for ISG15 gene… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-9 OF 9 CITATIONS

Similar Papers

Loading similar papers…